Ligand Pharma (LGND) Tops Q1 EPS by 36c, provides guidance

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.20, $0.36 better than the analyst estimate of $0.84. Revenue for the quarter came in at $30.98 million versus the consensus estimate of $26.69 million.

GUIDANCE:

Ligand Pharma sees FY2024 EPS of $4.25-$4.75, versus the consensus of $4.44. Ligand Pharma sees FY2024 revenue of $130-142 million, versus the consensus of $137.3 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• HSBC explains why risk assets continue to ignore every negative catalyst
• After an 18% summer selloff in chip stocks, Citi asks what comes next